Anson Funds Management’s Lunai Bioworks LNAI Stock Holding History

Anson Funds Management’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-140	Closed	-$22K	–	306
2022 Q2	$22K	Buy	+140	New	+$64K	﹤0.01%	318

Other funds holding LNAI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Anson Funds Management's LNAI Position: Q3 2022 in Review

Anson Funds Management sold out of Lunai Bioworks (LNAI) in Q3 2022, closing a stake of 140 shares — an estimated $22K sold.

Anson Funds Management first reported a position in LNAI in Q2 2022 and held it in 1 quarter. The position peaked at $22K in Q2 2022. 42 funds tracked by Wall St. Rank hold LNAI as of Q3 2022.

Anson Funds Management reported no remaining Lunai Bioworks position as of Q3 2022 after selling out during the quarter.
Anson Funds Management sold 140 Lunai Bioworks shares in Q3 2022, an estimated $22K.
Anson Funds Management first reported a position in Lunai Bioworks in Q2 2022 and held it in 1 quarter.
Anson Funds Management's Lunai Bioworks position peaked at $22K in Q2 2022.
42 funds tracked by Wall St. Rank held Lunai Bioworks as of Q3 2022.

Based on Anson Funds Management's 13F filing for Q3 2022, filed 15 Nov 2022.